Financial Contrast: Champions Oncology (CSBR) vs. The Competition

Champions Oncology (NASDAQ:CSBR) is one of 109 public companies in the “Life Sciences Tools & Services” industry, but how does it weigh in compared to its peers? We will compare Champions Oncology to related companies based on the strength of its dividends, earnings, institutional ownership, profitability, risk, analyst recommendations and valuation.

Analyst Ratings

This is a summary of recent ratings and price targets for Champions Oncology and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Champions Oncology	1	0	0	0	1.00
Champions Oncology Competitors	947	3162	5475	177	2.50

As a group, “Life Sciences Tools & Services” companies have a potential downside of 4.19%. Given Champions Oncology’s peers stronger consensus rating and higher probable upside, analysts plainly believe Champions Oncology has less favorable growth aspects than its peers.

Profitability

This table compares Champions Oncology and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Champions Oncology	-1.82%	-25.77%	-3.71%
Champions Oncology Competitors	-540.59%	-166.46%	-13.58%

Risk and Volatility

Champions Oncology has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500. Comparatively, Champions Oncology’s peers have a beta of 0.94, meaning that their average share price is 6% less volatile than the S&P 500.

Earnings & Valuation

This table compares Champions Oncology and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Champions Oncology	$59.42 million	-$1.17 million	-61.94
Champions Oncology Competitors	$2.26 billion	$55.88 billion	-13.93

Champions Oncology’s peers have higher revenue and earnings than Champions Oncology. Champions Oncology is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

41.3% of Champions Oncology shares are owned by institutional investors. Comparatively, 54.4% of shares of all “Life Sciences Tools & Services” companies are owned by institutional investors. 46.3% of Champions Oncology shares are owned by insiders. Comparatively, 15.2% of shares of all “Life Sciences Tools & Services” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Champions Oncology peers beat Champions Oncology on 9 of the 13 factors compared.

Champions Oncology Company Profile

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.